CNS Pharmaceuticals, Inc.

NEWS

Image of Houston downtown park and skyline in the morning

Business

Houston’s Life Sciences Scene Continues Boosting Its Reputation

While Houston isn’t yet on the same level as major life sciences hubs, it has plenty to offer and room to grow, according to CNS Pharmaceuticals, RadioMedix and Greater Houston Partnership executives.

March 13, 2025

6 min read

Angela Gabriel

IN THE PRESS

Lone Star Bio

CNS Pharmaceuticals to Participate in the Virtual Investor Glioblastoma Multiforme (GBM) Spotlight Event

April 12, 2022

4 min read

Lone Star Bio

CNS Pharmaceuticals Receives Approval from France Ethics Committee and Competent Authority for Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)

April 6, 2022

6 min read

Lone Star Bio

CNS Pharmaceuticals Receives Approval from Competent Authority of Switzerland for Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)

April 5, 2022

6 min read

Lone Star Bio

CNS Pharmaceuticals to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest

March 23, 2022

4 min read

Lone Star Bio

CNS Pharmaceuticals Reiterates Operational Progress and Addresses Recent Share Price Activity in Video to Shareholders

March 9, 2022

5 min read

Business

CNS Pharmaceuticals Reports Full Year 2021 Financial Results and Provides Corporate Update

March 3, 2022

8 min read

Lone Star Bio

CNS Pharmaceuticals to Present at the Virtual Investor 2022 Top Picks Conference

January 20, 2022

2 min read

Deals

CNS Pharmaceuticals Announces Closing of $11.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules

January 10, 2022

5 min read

Lone Star Bio

CNS Pharmaceuticals to Present at the H.C. Wainwright BioConnect Conference

January 7, 2022

1 min read

Lone Star Bio

CNS Pharmaceuticals Receives Approval from Switzerland Ethics Committee for its Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)

December 2, 2021

6 min read

JOBS